Home » Stocks » CPIX

Cumberland Pharmaceuticals, Inc. (CPIX)

Stock Price: $3.30 USD 0.08 (2.48%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.35 +0.05 (1.52%) Jan 22, 6:17 PM
Market Cap 49.55M
Revenue (ttm) 40.86M
Net Income (ttm) -3.42M
Shares Out 15.13M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.30
Previous Close $3.22
Change ($) 0.08
Change (%) 2.48%
Day's Open 3.20
Day's Range 3.12 - 3.58
Day's Volume 503,450
52-Week Range 2.90 - 5.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) ...

Seeking Alpha - 2 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Cumberland (CPIX) delivered earnings and revenue surprises of 128.57% and 7.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Cumberland (NASDAQ:CPIX) were flat after the company reported Q3 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.02, which beat the estimate ...

PRNewsWire - 2 months ago

NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 f...

Benzinga - 2 months ago

Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.

PRNewsWire - 2 months ago

NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after...

Zacks Investment Research - 2 months ago

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 months ago

ATLANTA, Sept. 28, 2020 /PRNewswire/ -- Women's apparel and fashion accessories retailer, Charming Charlie, today announced that it will open its first physical store at the Cumberland Mall in...

Business Wire - 4 months ago

SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #Calix--Cumberland Connect is deploying FTTH with Calix and has completed an end-to-end network integration 83 percent faster than industry standards

PRNewsWire - 5 months ago

NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Seeking Alpha - 5 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A.

Zacks Investment Research - 5 months ago

Cumberland (CPIX) delivered earnings and revenue surprises of 166.67% and 3.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Cumberland (NASDAQ:CPIX) rose 2.07% in after-market trading after the company reported Q2 results.

PRNewsWire - 5 months ago

NASHVILLE, Tenn., Aug. 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Benzinga - 5 months ago

Cumberland (NASDAQ: CPIX) releases its next round of earnings this Tuesday, August 11.

PRNewsWire - 5 months ago

NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

PRNewsWire - 6 months ago

NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

Zacks Investment Research - 7 months ago

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 7 months ago

NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcom...

Zacks Investment Research - 8 months ago

Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 8 months ago

NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today prov...

Zacks Investment Research - 8 months ago

Here are four top-ranked liquid gems that investors can add to portfolio for remarkable returns.

Other stocks mentioned: EXPI, MED, NPTN
Zacks Investment Research - 8 months ago

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: AMAG, MIST
Investopedia - 9 months ago

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: ALIM, OSG, RRTS, TTNP
Seeking Alpha - 10 months ago

Cumberland Pharmaceuticals Inc (CPIX) CEO A. J. Kazimi on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Cumberland (CPIX) delivered earnings and revenue surprises of -90.91% and -18.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.

Zacks Investment Research - 1 year ago

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

Zacks Investment Research - 1 year ago

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.

Zacks Investment Research - 1 year ago

Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.

Zacks Investment Research - 1 year ago

Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Seeking Alpha - 1 year ago

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET

Zacks Investment Research - 1 year ago

Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.

Zacks Investment Research - 1 year ago

Is (CPIX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Cumberland (CPIX) possesses solid growth attributes, which could help it handily outperform the market.

Seeking Alpha - 1 year ago

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2019 Results Earnings Conference Call May 14, 2019 4:30 PM ET

Zacks Investment Research - 1 year ago

Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

About CPIX

Cumberland Pharmaceuticals, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duo... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Aug 11, 2009
CEO
A. J. Kazimi
Employees
94
Stock Exchange
NASDAQ
Ticker Symbol
CPIX
Full Company Profile

Financial Performance

In 2019, CPIX's revenue was $47.53 million, an increase of 16.67% compared to the previous year's $40.74 million. Losses were -$3.54 million, -49.19% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CPIX stock is "Strong Buy" and the 12-month stock price forecast is 8.50.

Price Target
$8.50
Analyst Consensus: Strong Buy